Street Bullish on Cement, Infra, Auto and Banks
Fund managers and analysts participating in an ET Markets Poll expect the Nifty to gain further by the year end. 58% of participants feel the index could advance as much as 8% to 10% to 9,4009,600 by December. Nifty could rise to 9,000 to 9,400 by the yea
DID DECEMBER QUARTER EARNINGS REFLECT THE REAL IMPACT OF DEMONETISATION? steady as the company’s financials healthcare companies in the marBefore Dr Lal listing, VRL look promising,”saidKunjBansal,ED kets,” said Dharmesh Mehta, manLogistics’ debut in April at a premiand chief investment officer at aging director and CEO of Axis um of 40% to its issue price was the Mumbai: Drug maker Alkem CentrumWealthManagement. Capital. “We have seen that if the strongest. Inox Wind and Syngene Laboratories and diagnostic BIGGEST chain SURPRISEOn Dr IN Lal THE PathLabs,BUDGET Bansal NIFTYsaid DECEMBERIPOs is attractively2017 TARGET priced, there is International IPOs listed at a preDrLalPathLabsmadestellardebutsNo hike in STT and no LTCG Tax valuation of the company appears lot to be made by investors. There is mium of 35% and 24%, respectively. on the exchanges on Wednesday. expensive after the strong listing demandforpaperswherepromoters InterGlobe Aviation, the operator of Alkem listed 31% above its No issue negatives and investors should wait for the have good track record.” Indigo, which listed at almost 12% price,whileDrLalPathLabsopenedNo populist measure company’s financials now. Narayana Hrudayalaya’s IPO — premium to its IPO price of Rs760, is at a 50% premium — the best listing On Wednesday’s closing price, the last share sale in 2015 which currently trading 55% above its is
Maintaining fiscal prudence BIGGEST DISAPPOINTMENT IN THE BUDGET in 2015 — as investors who failed to Alkem’s market capitalisation is closedonMonday—wassubscribed sue price. get shares in the offerings lapped Others₹ 16,500 crore, trailing behind 8.63 times. them up on the opening day. The Wockhardt at ₹ 17,371 crore. Alembic Lowering The IPO10% surchagemarket in 2015 Agri has witNo hike in strong WILL twin RBI listingsCUT ensured that HOWthe MUCH Pharma? is valued at ₹ 13,000 crore.
corporate tax nessed on its salarybest run since 2010. spend Most istax slab primaryRATES NEXT market’s WEEK? winning run Sun Pharma, the leader of the pharsues have
above fetched50 lakh strong listing gains through 2015. ma pack, has market capitalisation forinvestors.SHKelkarandCo,aspeAlkemYes closed at ₹ 1,381 No on the BSE, of ₹ 1.90 lakh crore.25 bps
SECTORS cialty fragrance SECTORSand flavour ingrediLARGE CAPS up31.5%overitsissuepriceof ₹ 1,050 Alkem raised about ₹ 1,350 crore THAT WILLent maker, which THAT listed WILLin November, THAT WILL per share after touching a high of from its IPO, which was subscribed opened23%aboveitsIPOprice.
OUTPERFORM UNDEROUTPERFORM ₹ 1,410. Dr Lal closed at ₹ 824 over its 44.29 times, while Dr Lal’s ₹ 638-crore Thestrongperformancesaugurwell
IN 2017 PERFORM IN IN 2017 issue price of ₹ 550. issue was subscribed50 bps 33.41 times. for the IPO market in 2016, when a
Money managers said gains in The success of issues such as Cement strong pipeline of 2017 companies would Asian Paints both the shares are likely to be Alkem Labs and Dr Lal Path Labs Infra look to raise money Pharma through this Bank of Baroda capped after the strong listings. means companies have raised more Automobiles route,saidbrokersandbankers.Telecom HDFC Bank
“Alkem’slistingperformancewason than`13,000croresofarfromthepriBanks Metals SBI expectedlines,andweexpectthestock mary market in calendar 2015. FMCG Oil & Gas Sun Pharma performancetoremainmeasuredbut “There is strong appetite for Recap of PSU banks Others